Skip to content

Study · Observational study · n = 119 · 2006

5 results

Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.

Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM

The Journal of clinical endocrinology and metabolism31 Jan 2006Cited by 84 (Europe PMC)

PMID16449339 (opens in a new tab)DOI10.1210/jc.2005-1712 (opens in a new tab)PepBankPUB-16449339
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyOther

    In PTH-treated osteoporotic women, baseline turnover associations with subsequent areal and volumetric BMD changes were inconsistent.

    In plain wordsIn PTH-treated osteoporotic women, baseline bone turnover had inconsistent links to later bone density changes.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    MixedBaseline turnover and BMD response
    Study

    n = 119

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 mug/d · subcutaneous · 1 yrAs given in this study (human).

    Source sentences

    Summary
    Among women treated with PTH alone, the relationships between baseline turnover and 1-yr changes in dual-energy x-ray absorptiometry and QCT BMD were inconsistent.
    2 context sentences
    Summary · context
    Patients included 238 postmenopausal women with low hip or spine BMD.
    Summary · context
    Subjects were randomized to sc PTH (1-84), 100 mug/d (119 women), for 1 yr.
  2. 02HumanObservational studyOther

    In PTH-treated osteoporotic women, greater turnover increases at 1 and 3 months were associated with greater areal BMD increases.

    In plain wordsIn PTH-treated osteoporotic women, greater early bone turnover increases were linked to greater bone density gains.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseEarly turnover change and areal BMD
    Study

    n = 119

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 mug/d · subcutaneous · 1 yrAs given in this study (human).

    Source sentences

    Summary
    Greater 1- and 3-month increases in turnover, particularly the formation marker N-propeptide of type I collagen, were associated with greater increases in areal BMD.
    2 context sentences
    Summary · context
    Patients included 238 postmenopausal women with low hip or spine BMD.
    Summary · context
    Subjects were randomized to sc PTH (1-84), 100 mug/d (119 women), for 1 yr.
  3. 03HumanObservational studyOther

    In PTH-treated osteoporotic women, greater early turnover increases were positively associated with greater volumetric hip BMD increases at 1 yr.

    In plain wordsIn PTH-treated osteoporotic women, greater early turnover increases were linked to greater hip bone density gains.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseEarly turnover change and volumetric hip BMD
    Study

    n = 119

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 mug/d · subcutaneous · 1 yrAs given in this study (human).

    Source sentences

    Summary
    When volumetric hip and spine BMD were assessed by QCT, greater short-term increases in turnover were even more positively associated with 1-yr increases in BMD.
    2 context sentences
    Summary · context
    Patients included 238 postmenopausal women with low hip or spine BMD.
    Summary · context
    Subjects were randomized to sc PTH (1-84), 100 mug/d (119 women), for 1 yr.
  4. 04HumanObservational studyOther

    In PTH-treated osteoporotic women, greater early turnover increases were positively associated with greater volumetric spine BMD increases at 1 yr.

    In plain wordsIn PTH-treated osteoporotic women, greater early turnover increases were linked to greater spine bone density gains.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseEarly turnover change and volumetric spine BMD
    Study

    n = 119

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 mug/d · subcutaneous · 1 yrAs given in this study (human).

    Source sentences

    Summary
    When volumetric hip and spine BMD were assessed by QCT, greater short-term increases in turnover were even more positively associated with 1-yr increases in BMD.
    2 context sentences
    Summary · context
    Patients included 238 postmenopausal women with low hip or spine BMD.
    Summary · context
    Subjects were randomized to sc PTH (1-84), 100 mug/d (119 women), for 1 yr.
  5. 05HumanObservational studyOther

    In PTH-treated women, each SD increase in the 3-month N-propeptide change was associated with a 21% greater QCT spine trabecular BMD increase.

    In plain wordsIn PTH-treated women, larger early formation marker increases were linked to greater spine bone density gains.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseN-propeptide change and trabecular spine BMD
    Study

    n = 119

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 mug/d · subcutaneous · 1 yrAs given in this study (human).

    Measurements

    Greater BMD increase
    21%
    per SD of 3-month N-propeptide change

    Source sentences

    Summary
    Each sd increase in the 3-month change of N-propeptide of type I collagen was associated with an a 21% greater increase in QCT spine trabecular BMD.
    2 context sentences
    Summary · context
    Patients included 238 postmenopausal women with low hip or spine BMD.
    Summary · context
    Subjects were randomized to sc PTH (1-84), 100 mug/d (119 women), for 1 yr.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.